Event 16 Nov 2021

Interim report Q3 2021

Investors

Phase II company positioned for growth

Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and rare diseases market with a diversified portfolio of clinical and preclinical candidates.

A clinical phase II study is planned with CS1 for the treatment of the rare disease pulmonary arterial hypertension (PAH).

Pipeline

Therapeutics in common and rare cardiovascular disease

Cereno has a project portfolio targeting common and rare cardiovascular diseases. The aim is to develop treatments that can improve the life for affected patients. The portfolio comprises a Phase II program and two preclinical programs.

Therapeutic focus

Better efficacy and fewer side effects in focus

Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. Cereno has an extensive experience in cardiovascular diseases and works toward the aim of developing novel, better treatments to improve the health of cardiovascular patients, both in common and rare diseases.